CoChat

Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

Open access
Zarrinpar, A., Loomba, R. · 2012 · Alimentary Pharmacology & Therapeutics
Cited by 103

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Summary: Background: Recent research has led to an interest in the role of the gut and liver in type 2 diabetes mellitus (T 2 DM). Aim: To review the role of the gastrointestinal system in glucose homoeostasis, with particular focus on the effects of incretin hormones, hepatic steatosis and bile acids. Methods: PubMed and Google Scholar were searched using terms such as incretin, glucose‐dependent insulinotropic polypeptide (GIP), glucagon‐like peptide‐1 (GLP‐1), dipeptidyl peptidase‐4 (DPP‐4), hepatic steatosis, bile acid and gastric bypass. Additional relevant references were identified by reviewing the reference lists of articles. Results: Perturbations of incretin hormones and bile acid secretion contribute to the pathogenesis of T 2 DM, leading to their potential as therapeutic targets. The incretin hormones (GIP and GLP‐1) are deactivated by DPP‐4.GLP‐1 agonists and DPP‐4 inhibitors improve glycaemic control in patients with T 2 DM. Hepatic steatosis, along with insulin resistance, may precede the development of T 2 DM, and may benefit from anti‐diabetes medications. Bile acids play an important role in glucose homoeostasis, with effects mediated via the farnesoid X receptor (FXR) and the cell surface receptor TGR 5. The bile acid sequestrant colesevelam has been shown to be effective in improving glycaemic control in patients with T 2 DM. Altered gastrointestinal anatomy after gastric bypass surgery may also affect enterohepatic recirculation of bile acids and contribute to improved glycaemic control. Conclusions: Research in recent years has led to new pathways and processes with a role in glucose homoeostasis, and new therapeutic targets and options for type 2 diabetes mellitus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.12084

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

Metadata

Authors
Zarrinpar, A., & Loomba, R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-10-11
Volume
36
Issue
10
Pages
909-921
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2069053014
Cited by
103
References
53
FWCI
9.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.